» Articles » PMID: 8661635

Peritoneal Carcinomatosis from Adenocarcinoma of the Colon

Overview
Journal World J Surg
Publisher Wiley
Specialty General Surgery
Date 1996 Jun 1
PMID 8661635
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Peritoneal carcinomatosis is a major cause of surgical treatment failure in patients with colorectal cancer. In the past patients with this condition have had a lethal outcome. In this study, 64 consecutive patients were treated by the cytoreductive approach, which involved surgery to maximally resect all cancer in the abdomen and pelvis, early postoperative intraperitoneal chemotherapy with 5-fluorouracil (5-FU) and mitomycin C, and three cycles of adjuvant intraperitoneal 5-FU with systemic mitomycin C. The clinical features that may affect prognosis were assessed and critically analyzed statistically. Peritoneal implant size of < 5 cm present in the abdomen and pelvis at the time of exploration correlated with a good prognosis (p < 0.0001), as did complete cytoreduction with tumor removed to nodules < 2.5 mm (p < 0.0001). Involvement of only one or two of the five abdominopelvic regions, compared to three or more regions, was a significant determinant of prognosis (p < 0.0001). Finally, a mucinous histologic type correlated adversely with prognosis when compared to intestinal-type adenocarcinomas (p < 0.001). These data suggest that patients with small-volume peritoneal seeding from colon cancer should be treated with cytoreductive surgery and aggressive regional and systemic chemotherapy in an attempt to achieve long-term disease-free survival.

Citing Articles

Clinical Effectiveness of Preoperative 18F-FDG PET/CT in Predicting Pathological Tumor Grade in Patients with Pseudomyxoma Peritonei Originating from Appendix: A Retrospective Cohort Study.

Aso K, Gohda Y, Hotta M, Minamimoto R, Shimizu Y, Uemura Y Ann Surg Oncol. 2023; 31(3):1990-1995.

PMID: 38082170 DOI: 10.1245/s10434-023-14755-y.


A Prediction Model for Metachronous Peritoneal Carcinomatosis in Patients with Stage T4 Colon Cancer after Curative Resection.

Tsai T, You J, Hsu Y, Jhuang J, Chern Y, Hung H Cancers (Basel). 2021; 13(11).

PMID: 34200032 PMC: 8200190. DOI: 10.3390/cancers13112808.


The Landmark Series: Surgical Treatment of Colorectal Cancer Peritoneal Metastases.

Bijelic L, Ramos I, Goere D Ann Surg Oncol. 2021; 28(8):4140-4150.

PMID: 33969466 DOI: 10.1245/s10434-021-10049-3.


Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative.

Zaidi M, Lee R, Gamboa A, Speegle S, Cloyd J, Kimbrough C Ann Surg Oncol. 2019; 27(1):156-164.

PMID: 31602579 PMC: 7195626. DOI: 10.1245/s10434-019-07626-y.


Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.

Narasimhan V, Das A, Warrier S, Lynch C, McCormick J, Tie J Langenbecks Arch Surg. 2019; 404(5):527-539.

PMID: 31377856 DOI: 10.1007/s00423-019-01805-x.


References
1.
Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S . Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg. 1993; 17(2):256-61; discussion 261-2. DOI: 10.1007/BF01658939. View

2.
Jacquet P, Jelinek J, Steves M, Sugarbaker P . Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993; 72(5):1631-6. DOI: 10.1002/1097-0142(19930901)72:5<1631::aid-cncr2820720523>3.0.co;2-i. View

3.
Hughes K, Simon R, Songhorabodi S, ADSON M, Ilstrup D, Fortner J . Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986; 100(2):278-84. View

4.
Sugarbaker P, Jablonski K . Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995; 221(2):124-32. PMC: 1234945. DOI: 10.1097/00000658-199502000-00002. View

5.
Sugarbaker P . Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996; 82:79-100. DOI: 10.1007/978-1-4613-1247-5_6. View